2026-07-23T20:22:24Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/228222024-09-10T13:10:37Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967

00925njm 22002777a 4500 dc Gomez-Lobon, Ana author Serrano Lopez De Las Hazas, Joaquin author Fanjul, Francisco author Rovira Torres, Pilar author Vanrell Ballestero, Ana author Payeras Cifre, Antonio author Riera, Melchor author 2019 Introduction: Since 2015, integrase strand transfer inhibitors (INSTI)-based regimens have been considered as the preferred option for antiretroviral therapy (ART)-naive patients. The main objective of this study was to identify the ART-regimens selected for treatment-naive patients during 2015 in two tertiary hospitals, determine the rate of virological failure at 24 and 48 weeks, and compare the results with those of previous years (2012-2014). Material and methods: Four-year retrospective study. Adult ART-naive patients who had started treatment between 2012 and 2015 were selected. Clinical data, laboratory tests performed, and ART selected were recorded. Results: A total of 536 patients were included, 137 from 2015 and 399 from 2012-2014. The most common ART regimens prescribed in 2015, compared to 2012-2014, were INSTI-based regimens (68.6% vs. 4.8%), followed by non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens (20.4% vs. 52.8%) and PI-based regimens (10.9% vs. 42.5%). Most patients received a single-tablet regimen (78.8% vs. 51.9%). In 2015, 72.3% of patients had a viral load (VL) < 50 copies/ml at week 24 and 83.9% at week 48, compared to 55.1% and 74.7%, respectively, in 2012-2014. During the 48-week follow-up, the ART regimen was changed in 22.6% of patients in 2015 and 29.3% in 2012-2014. The main reason was simplification (45.2% vs. 22.2%) followed by side effects (25.8% vs. 38.5%). Conclusions: In 2015, INSTI-based regimens were prescribed in nearly 70% of ART-naive patients. This change in trend in the starting ART regimen results in a greater number of patients achieving a VL < 50 copies/ml at weeks 24 and 48 and in a reduction in ART changes due to adverse effects. Gomez-Lobon A, Lopez Hazas J Serrano, Fanjul F, Rovira Torres P, Vanrell Ballesteros A, Payeras Cifre A, et al. Effectiveness of antiretroviral therapy in treatment-naive patients. Results at 24 and 48 weeks. HIV AIDS Rev. 2019;18(2):100-6. 10.5114/hivar.2019.86374 1732-2707 1730-1270 HIV & AIDS Review http://hdl.handle.net/20.500.13003/17268 L2002428004 2-s2.0-85069965152 https://hdl.handle.net/20.500.12105/22822 474917200004 Adult anti-HIV agents HIV infections Treatment outcome Viral load Effectiveness of antiretroviral therapy in treatment-naive patients. Results at 24 and 48 weeks